Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 13/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095754 | 1.00 | PDE9A (0.39) | PDE9APDE1CSRCADORA1ABL1 | |
| SCHEMBL29174763 | 0.85 | LRRK2 (0.38) | PDE1CADORA1 | |
| SCHEMBL30095696 | 0.85 | LRRK2 (0.38) | PDE1CADORA1 | |
| SCHEMBL29174930 | 0.84 | ADORA2A (0.37) | PDE1CADORA1 | |
| SCHEMBL30748232 | 0.84 | ADORA2A (0.37) | PDE1CADORA1 | |
| SCHEMBL30748221 | 0.83 | PDE9A (0.41) | PDE9APDE1C | |
| SCHEMBL29174835 | 0.83 | PDE9A (0.41) | PDE9APDE1C | |
| SCHEMBL30748216 | 0.83 | PDE9A (0.41) | PDE9APDE1C | |
| SCHEMBL29174873 | 0.82 | KDM4E (0.46) | PDE9APDE1C | |
| SCHEMBL30095907 | 0.82 | KDM4E (0.46) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-15 | — | — | US | disclosed |
| CN-117529315-A | Imidazole-containing ALK2 kinase inhibitors | 生物水晶制药公司 | 2024-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PDE9A 423/4885PDE1C 953/4885SRC 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.